FUSE artikel uit The Lancet - februari 2014
“Standard forward-viewing colonoscopy versus full-spectrum endoscopy: an international, multicentre, randomized, tandem colonoscopy trial”.
Prof. Ian M Gralnek MD, Peter D Siersema MD, Zamir Halpern MD, Ori Segol MD, Alaa Melhem MD, Erwin Santo MD, Alan Sloyer MD, Jay Fenster MD, Leon M G Moons MD, Vincent K Dik MD, Ralph B D´Agostino PhD, Douglas K Rex MD.
We are very happy to announce that as of Thursday the 20th of February 2014, the Fuse Study - "Standard forward-viewing colonoscopy versus full-spectrum endoscopy: an international, multicentre, randomized, tandem colonoscopy trial” is live on The Lancet Oncology’s website. With this announcement, you can begin discussing, referencing, and, most importantly, leveraging The Lancet Oncology data with GI caregivers across the world:
- 69% incremental adenoma detection rate;
- Fuse adenoma miss rate: 7% Standard forward view (SFV) adenoma miss rate: 41%;
- Zero false negative colonoscopies with Fuse first;
- 6% of patients with SFV first had a false negative colonoscopy;
- 53% of patients with adenomas missed by SFV had their surveillance rate changed by Fuse (9% of total study population).
|
  |
